the only applications we have heard are Teva and Amphastar... And as far as we could tell Amphastar's application has problems(?)...Teva's ANDA nobody should undermine..they have the muscle to get this through...plus FDA replying to Sanofi's CP and detailing criteria for approval, prolly helps TEVA quite a bit. I am hoping mL's IP has potential to block tL...but that also does not seem very clear